Genetic Signatures Signs 10-Year Danish Deal While Cutting $5M in Annual Costs

Sales Reflect Seasonal Respiratory Testing Trends

Genetic Signatures (ASX:GSS) reported quarterly sales of $3 million for Q3 FY2026, a figure shaped by the typical seasonal ebb in respiratory testing demand across Australia. Receipts from customers were $3.7 million, but the company recorded a net operating cash outflow of $3.5 million for the quarter. Despite this, the company maintains a robust balance sheet with $25.7 million in cash and term deposits as of 31 March 2026, providing a solid runway for ongoing operations and strategic initiatives.

$5 Million Annual Cost Savings from Organisational Restructure

Following a strategic review, Genetic Signatures implemented a significant organisational restructuring that resulted in 30 redundancies across five divisions, balanced by the creation of three new roles focused on project management and outsourcing. This overhaul is expected to deliver $5 million in annualised cost savings starting FY2027. The company incurred one-off redundancy costs of $0.8 million in April 2026, to be reflected in the upcoming quarter’s cash flow. This move aligns with the company’s broader efforts to sharpen operational efficiency and accelerate growth, as outlined in their recent reshapes operations to slash costs announcement.

Strategic Shift to Outsourced Product Development

In a bid to reduce fixed costs and speed up product commercialisation, Genetic Signatures has started transitioning elements of its product development to specialist contract research organisations. While maintaining core intellectual property and technical capabilities internally, this model aims to access best-in-class expertise flexibly. The company emphasises that this pragmatic approach is essential to drive adoption of its EasyScreen™ molecular diagnostic platform across multiple jurisdictions and market segments.

Long-Term Supply Deal in Denmark Boosts European Footprint

April 2026 saw Genetic Signatures secure a ten-year supply agreement with Denmark’s Hvidovre Hospital, covering equipment and reagents for gastrointestinal screening of 28,000 clinical samples in the first year, with an anticipated 3% annual growth. This contract includes a reagent and consumables supply agreement extendable by two additional 12-month periods. Installation and validation are underway, with commercial orders expected to commence in September 2026. This deal not only underscores the clinical and commercial potential of the EasyScreen™ platform but also marks a significant milestone in the company’s European expansion strategy, building on momentum from the decade-long Danish contract secured earlier in April.

CEO to Outline Strategic Progress in June Briefing

Genetic Signatures plans an investor briefing in early June 2026, led by CEO Maria Halasz, who marked her first 90 days in office. The briefing will detail the outcomes of the comprehensive strategic review, including operational restructuring, market focus across Australia, the US, Europe, and other growth opportunities. Halasz is expected to discuss plans to reset US operations while capitalising on the growing momentum in EMEA markets. The company continues to prioritise scaling through commercial partnerships and organic growth, aiming to enhance shareholder value over the long term.